Table 1.

Clinical and pathologic features of ALK-positive patients at baseline

CharacteristicAll patients (N = 73)
Age at diagnosis
 Median50
 Range22–72
Sex, n (%)
 Male38 (52)
 Female35 (48)
Ethnicity, n (%)
 Caucasian54 (74)
 Asian17 (23)
 Other2 (3)
Smoking history, n (%)
 Never57 (78)
 Light (≤10 pack years)10 (14)
 Heavy (>10 pack years)6 (8)
Histology, n (%)
 Adenocarcinoma69 (95)
 Squamous3 (4)
 Adenosquamous1 (1)
Stage at diagnosis, n (%)
 Stage I–II2 (3)
 Stage III–IV71 (97)
Lines of therapy before crizotinib a
 010 (14)
 132 (44)
 216 (22)
 37 (10)
 4–88 (11)
Brain metastases before crizotinib, n (%) b
 Present25 (35)
 Absent47 (65)
  • aAll patients received crizotinib before eventual treatment with ceritinib.

  • bNeuroimaging was not available in one patient.